Margaret Liang

Margaret Liang
Assistant Professor

Associate Scientist (C), O'Neal Comprehensive Cancer Center , School of Medicine
Associate Scientist, Cancer Control and Population Sciences , O'Neal Comprehensive Cancer Center
Associate Scientist (C), Center for Women's Reproductive Health , General Clinical Research Center
Assistant Professor (P), OB/GYN - Gyn Oncology , OB/GYN

Overview

I grew up in Ohio and completed my undergraduate, medical school, and residency training at The Ohio State University. I then went on to complete my fellowship training in gynecologic oncology at UCLA and Cedars-Sinai Medical Center in Los Angeles. I moved to Birmingham to work at UAB because of the amazing multi-disciplinary cancer care team that we have. The UAB health system and Cancer Center are dedicated to being at the cutting edge of providing high quality and well coordinated cancer care.

Selected Publications

Academic Article

Year	Title	Altmetric
2021	Measuring Financial Distress and Quality of Life Over Time in Patients With Gynecologic Cancer-Making the Case to Screen Early in the Treatment Course 2021
2021	Evaluating meaningful levels of financial toxicity in gynecologic cancers. International Journal of Gynecological Cancer. 31:801-806. 2021
2021	The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?. Gynecologic Oncology. 160:800-804. 2021
2021	Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. Gynecologic Oncology. 160:793-799. 2021
2020	How, when, and with whom should cost of care conversations occur? preferences of two distinct cancer survivor groups 2020
2020	Extensive financial hardship among gynecologic cancer patients starting a new line of therapy. Gynecologic Oncology. 156:271-277. 2020
2020	Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. Gynecologic Oncology. 2020
2019	Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. International Journal of Gynecological Cancer. 29:1156-1163. 2019
2019	Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012)). Gynecologic Oncology. 154:449. 2019
2019	Perspectives on conversations about costs of cancer care of breast cancer survivors and cancer center staff: A qualitative study. Annals of Internal Medicine. 170:S54-S61. 2019
2019	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. 152:445-451. 2019
2019	Emerging From the Haze: A Pilot Study Evaluating Feasibility of a Psychoeducational Intervention to Improve Cancer-Related Cognitive Impairment in Gynecologic Cancer Survivors.. Journal of Palliative Care. 34:32-37. 2019
2019	Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Journal of Surgical Oncology. 120:779-785. 2019
2018	Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.. Gynecologic Oncology. 151:501-505. 2018
2018	Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman. Gynecologic Oncology. 151:6-9. 2018
2018	Financial toxicity – An overlooked side effect. Gynecologic Oncology. 150:3-6. 2018
2018	Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers. Journal of Genetic Counseling. 27:177-186. 2018
2017	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. Journal of Oncology Practice. 13:e1030-e1039. 2017
2015	Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications. International Journal of Gynecological Cancer. 25:1271-1276. 2015
2015	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.. Gynecologic Oncology. 138:689-693. 2015
2015	Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer. 2015
2014	Training the next generation of robotic surgeons using guided mentorship: a randomized controlled trial. 2014
2013	Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.. Gynecologic Oncology. 131:508-511. 2013
2011	Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. Journal of Controlled Release. 151:239-245. 2011
2008	Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature.. World Journal of Surgical Oncology. 6:117. 2008
2008	Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy.. World Journal of Surgical Oncology. 6:79. 2008
2007	Current immunotherapeutic strategies in breast cancer.. Surgical Oncology Clinics of North America. 16:841-ix. 2007

Research Overview

I am interested in studying the out of pocket costs that gynecologic cancer patients face while undergoing diagnosis, treatment, and follow-up. These costs can lead patients to experience financial distress and decrease in quality of life.

I am working to develop ways to provide:
- universal screening for financial distress
- improved communication about the anticipated costs of care
- resources to identify assistance programs and decrease this financial burden on patients
- education for patients to help them plan and make informed decisions with their health care providers